All In Biotech

Drug Trial Radar · NCT02583373

Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae

Randomised, Multicentre, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy and Pharmacodynamics After the Intravenous Administration of CAL02 in Severe Community-acquired Pneumonia Due to Streptococcus Pneumoniae

Last checked: Nov 19, 2026Latest source record: Jan 27, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Mar 21, 2016

Primary completion

Feb 20, 2018

Study completion Feb 20, 2018

Sponsor

Lead sponsor
Combioxin SAIndustry
Sponsor type
Industry
First posted
Oct 22, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are to assess the safety, tolerability, clinical and microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by Streptococcus pneumoniae after the intravenous administration of CAL02 in addition of standard of care antibiotic treatment.

Conditions

  • Pneumonia
  • Pneumococcal Infections

Interventions

  • CAL02 Low-doseDrug

    Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion

  • CAL02 High-doseDrug

    Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion

  • PlaceboDrug

    Placebo administered administered 2 times (24 hours apart) as i.v. infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency, severity and characteristics of adverse events after two iv. administrations of CAL02.Time frame: 29 days

Locations

10 sites in 2 countries. Site status is shown where the registry gives one.

  • St Luc University Hospital

    Brussels, Belgium

  • University Hospital Brussels

    Brussels, Belgium

  • Clinique St Pierre

    Ottignies, Belgium

  • CHU Jean Minjoz

    Besançon, France

  • CHD Les Oudairies

    La Roche-sur-Yon, France

  • Hôpital Mignot

    Le Chesnay, France

  • CHU Dupuytren

    Limoges, France

  • Centre Hospitalier Régional d'ORLEANS

    Orléans, France

  • CH Yves Le Foll

    Saint-Brieuc, France

  • CHRU de Tours

    Tours, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.